Reunion Neuroscience Inc.
News
Reunion Neuroscience Inc. and MPM BioImpact Announce Completion of Plan of Arrangement
Globe Newswire TORONTO, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (TSX: REUN, NASDAQ: REUN) ("Reunion" or the "Company"), a clinical-stage biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions and MPM BioImpact ("...\n more…
Terran Biosciences Steps Into 4-OH-DiPT Prodrug Arena With New Patent Application
Benzinga As Reunion Neuroscience (NASDAQ: REUN) and Mindset Pharma (OTCMKTS: MSSTF) continue their court battle over claims on a novel 4-OH-DiPT prodrug, private biotech company Terran Biosciences has also filed a patent application over a proprietary polymorph,\n more…
Reunion Neuroscience On The Brink Of Going Private With Final Court Approval
Benzinga Clinical-stage psychedelics company Reunion Neuroscience (NASDAQ: REUN) is about to close on its take-private transaction with MPM BioImpact affiliates, as shareholders voted for a special resolution approving the proposed arrangement plan on July 12.\n more…
Reunion Neuroscience Inc. Obtains Final Court Order for Proposed Plan of Arrangement
Globe Newswire TORONTO, July 14, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (TSX: REUN, NASDAQ: REUN) ("Reunion" or the "Company"), a clinical-stage biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions is pleased to ...\n more…
Reunion Neuroscience shareholders approve acquisition by MPM BioImpact
Seeking Alpha - Healthcare Reunion Neuroscience (REUN) said on Thursday that its shareholders have approved a proposed acquisition of the biopharmaceutical company by the affiliates of MPM BioImpact.\n more…